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Abstract
Background: Dendritic cells (DC) can act tolerogenic at a semi-mature stage by induction of protective CD4+ T cell and NKT
cell responses.
Methodology/Principal Findings: Here we studied the role of the co-inhibitory molecule B7-H1 (PD-L1, CD274) on semi-
mature DC that were generated from bone marrow (BM) cells of B7-H12/2 mice and applied to the model of Experimental
Autoimmune Encephalomyelitis (EAE). Injections of B7-H1-deficient DC showed increased EAE protection as compared to
wild type (WT)-DC. Injections of B7-H12/2 TNF-DC induced higher release of peptide-specific IL-10 and IL-13 after
restimulation in vitro together with elevated serum cytokines IL-4 and IL-13 produced by NKT cells, and reduced IL-17 and
IFN-c production in the CNS. Experiments in CD1d2/2 and Ja2812/2 mice as well as with type I and II NKT cell lines
indicated that only type II NKT cells but not type I NKT cells (invariant NKT cells) could be stimulated by an endogenous
CD1d-ligand on DC and were responsible for the increased serum cytokine production in the absence of B7-H1.
Conclusions/Significance: Together, our data indicate that BM-DC express an endogenous CD1d ligand and B7-H1 to ihibit
type II but not type I NKT cells. In the absence of B7-H1 on these DC their tolerogenic potential to stimulate tolerogenic
CD4+ and NKT cell responses is enhanced.
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Introduction
DC are not only potent inducers of adaptive immune responses
but also mediators of tolerance. Immature DC, which do not express
maturation markers and produce no cytokines are considered to be
tolerogenic. Fully mature DC upregulate maturation markers upon
stimulation and produce cytokines and are therefore termed
immunogenic. In addition another maturation stage has been
characterized as semi-mature DC [1]. These cells which upregulate
maturation markers but do not produce cytokines are tolerogenic
and can protect mice from EAE by inducing protective CD4+ T cell
and NKT cells responses [2,3].
For efficient T cell activation and the generation of functionally
competent effector cells, additional costimulatory signaling through
surface molecules on APC and T cells is needed [4]. Upregulation of
T cell activity by attenuation of coinhibitory signals provides an
attractive tool for the treatment of autoimmune and inflammatory
diseases [5]. Among the B7-CD28 family of costimulatory
molecules, B7-H1 on APC has been proposed to regulate immune
responses by interaction with PD-1 or CD80 (B7-1) and possibly
another yet unidentified receptor on activated T cells [6,7,8]. B7-H1
is widely expressed on different cell populations including T and B
cells, monocytes, DC, but also non-hematopoietic cells [9,10]. Its
receptor PD-1 is inducible on T and B cells upon activation [11].
Due to their broad tissue expression pattern, B7-H1/PD-1
interactions have been implicated in critically modulating paren-
chymal inflammation, limiting autoimmune responses and confin-
ing immune cell functions in the periphery [12,13,14,15].
Originally, interactions of B7-H1/PD-1 were postulated to
costimulate T cell activation and proliferation [16], but more
recent data point towards a negative regulatory role of the B7-H1/
PD-1 pathway in T cell activation, proliferation and CTL activity
[6,9,17,18]. Using the animal model of MS, EAE, this coinhibi-
tory effect mediated by B7-H1 has been extensively studied
[12,15,19,20,21,22]. It was demonstrated that systemic absence of
B7-H1 renders 129Sv mice susceptible to EAE and exacerbates
disease in C57BL/6 mice [6,15,21]. Additionally, blockade of B7-
H1 or PD-1 with specific antibodies resulted in increased
susceptibility and progression of EAE in various mouse strains
[20,23]. While B7-H1 expression in the CNS was shown to be very
limited under physiological conditions, it is rapidly upregulated
during inflammation [19]. Particularly microglial cells expressing
inhibitory B7-H1 were found to dampen encephalitogenic T cell
responses in later stages of EAE, suggesting a major contribution
of this molecule to confinement of parenchymal inflammation
[12,22]. Similar conclusions were drawn from experiments using
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an animal model of diabetes, where PD-1/B7-H1 interactions
were shown to regulate effector cell differentiation of autoreactive
CD8+ T cells during the presentation of tissue antigens [13].
However, little is known about the role of the B7-H1/PD-1
pathway in mediating tolerogenicity during protection against
neuroinflammation.
In this study, we investigated the role of B7-H1 on tolerogenic
DC in mediating tolerance induction in the context of autoimmune
inflammation. After intravenous injections of TNF- treated semi-
mature DC deficient in B7-H1 we found a stronger tolerogenic
capacity in EAE protection in comparison to WT DC. In the CNS,
we found no differences in total CD4 and CD8 T cell infiltration,
but lower numbers of neuroantigen-specific IFN-c and IL-17
producing cells. The ameliorated EAE phenotype was accompanied
by increased production of the protective cytokines IL-10 and IL-13
and reduced levels of proinflammatory IFN-c and IL-17 in the
periphery. Additionally, we observed higher serum cytokine levels of
IL-4 and IL-13 in B7-H12/2 DC injected mice, which contributed
to the tolerance induction. We found that type II cells but not type I
invariant NKT (iNKT) cells were the producers of these cytokines.
It has been described that the B7-H1/PD1 pathway is involved in
the activation of iNKT cells [24,25]. We found that the signaling via
B7-H1 on the DC does not influence the iNKT response but it has
an impact on other CD1d-restricted cells. It has been shown that in
mice lacking the MHC class II molecule there is still a population of
T cells other than iNKT cells, which recognize the CD1d molecule.
Now we show that these type II NKT cells are regulated by B7-H1
[26,27]. Our data describe the importance of B7-H1/type II NKT
cell interactions and its unexpected impact by modulation of
tolerogenic DC in EAE protection.
Results
DC from WT and B7-H12/2 mice show a similar
expression of surface markers and have the same
potential to stimulate CD4+ T cells
We compared TNF-matured DC from WT and B7-H12/2
mice regarding their surface markers and their stimulatory
capacity. FACS analysis of these DC showed a comparable
expression of CD80, CD86, CD40, MHC II and B7-DC (PD-L2)
on their cell surface and despite the loss of B7-H1 in the knock-out
mice (Figure 1A). We further investigated the potential of WT and
B7-H12/2 DC to stimulate T cells. Therefore enriched CD4+
T cells derived from 2D2 mice bearing a TCR specific for
MOG35–55 were co-cultured with MOG-loaded DC from WT and
B7-H12/2 mice. The CD4+ T cells show comparable proliferation
rates after incubation with WT or B7-H12/2 DC as indicated by
CFSE-dilution (Figure 1B).
Higher tolerogenic potential of B7-H12/2 DC in EAE
We previously demonstrated that repetitive i.v. injections of
semi-mature DC, which were stimulated with TNF and loaded
with MOG35–55 peptide, were able to protect mice from
developing EAE [3]. Mechanisms involved in the mediation of
tolerance revealed the induction of IL-10 producing CD4+ T cells
as well as the activation of NKT cells, which in turn rapidly
produced protective cytokines contributing to the tolerogenic
capacity of the semi-mature DC [2,3]. To investigate the role of
the coinhibitory molecule B7-H1 on tolerance induction we
injected WT mice 7, 5 and 3 days before EAE induction with
different numbers of MOG35–55 peptide loaded and TNF-matured
WT and B7-H12/2 DC. We found that PBS-injected control mice
developed severe EAE, whereas TNF-DC-injected mice were
partially or fully protected from disease depending on the number
and phenotype of applied TNF-DC (Figure 2A, Table 1). Mice
injected with a suboptimal dose of WT TNF-DC (26106)
displayed a slightly ameliorated EAE course compared to control
animals, increase in TNF-DC numbers resulted in a more
pronounced protective phenotype. In contrast, B7-H12/2 TNF-
DC injected mice were fully protected from clinical signs of EAE,
even at suboptimal doses of TNF-DC. To assess antigen specificity
requirements for EAE tolerance induction, mice were treated with
TNF-matured DC but without MOG35–55 before EAE induction.
Here, no protective effect of both WT and B7-H1-deficient DC
was observed, indicating that the induction of tolerance by
injection of DC is neuroantigen-specific and dependent on the
presentation of MOG35–55 peptide by DC (Figure 2B).
Injection of B7-H12/2 TNF-DC reduces the frequency of
neuroantigen-specific cytokine-secreting T cells in the
CNS
To address the amount of total T cell infiltration in the
target organ of EAE-affected mice, we performed flow cytometry
to quantify the abundance of CNS infiltrating T cells in the
inflamed brains and spinal cords. 15 days after EAE induction an
equal percentage of both CD4+ and CD8+ T cell populations
could be detected in all three investigated groups (Figure 3A). To
further characterize the cytokine production by CNS-infiltrating
T cells, ELISPOT analyses following MOG35–55 restimulation
revealed highest frequency of neuroantigen-specific IFN-c and
IL-17-producing cells in the CNS of PBS-injected mice (Figure 3B).
WT TNF-DC injection resulted in a noticeable and consistent
reduction of both IFN-c (92614 spots) and IL-17 (1565 spots)
producing CNS cells, although the differences were not statistically
significant in comparison to the control group (130611 spots
for IFN-c, 1866 for IL-17) in two performed experiments. In
contrast, using B7-H1-deficient TNF-DC injection prior to
EAE induction, a marked decline in IFN-c positive spots to
2868 spots could be observed in the CNS of disease-protected
animals. Again, the frequency of IL-17 secreting cells was reduced,
but differences did not yield statistical significance (361 spots).
CNS localized IL-10 production by MOG35–55 specific cells was
also assessed but found undetectable in either group of mice (data
not shown).
These data provide evidence that TNF-DC injection does not
considerably influence total CNS T cell infiltration, but rather
modulates the local cytokine milieu. Correlating to the EAE
disease course, proinflammatory cytokines are substantially
reduced upon B7-H12/2 TNF-DC administration.
Injection of B7-H12/2 TNF-DC modulates primary
neuroantigen-specific T cell responses in the periphery
To assess the mechanism of increased EAE suppression in the
absence of B7-H1 on tolerogenic DC, the spleens of PBS- or
TNF-DC-injected mice were removed 10 days after EAE
induction and peripheral T cell responses were investigated.
Splenocytes were challenged with MOG35–55 peptide and after
72 hours cell culture supernatants were analyzed for their cytokine
content by ELISA. In PBS-injected control mice the predominant
cytokines that could be detected after MOG35–55 peptide titration
were proinflammatory IFN-c and IL-17, whereas only little
protective IL-10 and IL-13 were present (Figure 4). By contrast,
splenocytes from WT TNF-DC-injected mice produced large
amounts of IL-10 and IL-13 even in the absence of or under low
concentrations of neuroantigen. Simultaneously, secreted levels of
IFN-c were similar to the control group and IL-17 was modestly
reduced compared to PBS-injected mice. Interestingly, this
Type II NKT Cells
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TNF-DC-mediated effect on cytokine profile modulation was even
more pronounced in the absence of B7-H1 on injected TNF-DC.
Here, we found a markedly reduced production of IFN-c that was
dependent on the MOG35–55 peptide concentration during spleen
cell culture. Similarly, only small amounts of IL-17 could be
detected in the supernatants. However, in B7-H12/2 TNF-DC-
injected mice peripheral levels of IL-13 were dramatically
increased compared to both PBS- and WT TNF-DC-injected
mice. This effect was found to be only partially neuroantigen-
restricted, as higher concentrations of MOG35–55 peptide further
enhanced IL-13 production. High peripheral IL-13 concentrations
were also accompanied by an increased basal amount of IL-10 in
B7-H12/2 DC injected animals.
Together, these data indicate that TNF-DC injections induce
the production of protective cytokines and downregulates
potentially pathogenic master cytokines. In correlation with the
reduced disease courses, this effect is more distinct in the absence
of B7-H1 on TNF-DC.
Injection of B7-H12/2 TNF-DC induces increased
production of protective serum cytokines, which are
predominantly produced by type II but not type I NKT
cells
We showed previously that TNF-DC induce a rapid production
of type 2 cytokines detectable in mouse sera early after the third
injection of TNF-DC and their contribution to EAE prevention by
constraining Th1 and Th17 effector cell development [2]. As a
prerequisite we tested the PD-1 expression on the cell surface by
type I and II NKT cells of WT mice and the type II NKT cells of
Ja2812/2 mice and could not find major differences (Figure 5A).
To determine the relevance of TNF-DC B7-H1 expression for
protective cytokine production, sera from WT or B7-H12/2 TNF-
DC-injected mice were collected and analyzed for cytokine profile
by ELISA. While IL-17 concentration was generally low and
remained unaffected by TNF-DC treatment (data not shown),
TNF-DC-injected mice displayed significantly elevated levels of
IFN-c in their sera (Figure 5B). This effect was even reinforced in
Figure 1. WT and B7-H12/2 DC show equal expression of surface markers and have the same potential to stimulate CD4+ T cells. A)
BM-derived DC from WT and B7-H12/2 mice were matured with TNF over night, stained for different surface markers and analyzed by flow
cytometry. The shaded histograms show the unstimulated control and the black lines show TNF-matured DC. Results are representative for 3
independent experiments. B) TNF-stimulated and MOG35–55-loaded DC from WT and B7-H1
2/2 mice were co-cultured with CFSE-stained CD4+ T cells
with MOG35–55 transgenic TCR. Proliferation of the T cells was analysed by the dilution of the CFSE-staining. The dottet line shows the control without
DC, the shaded histogram shows the co-culture with 16104 DC and the filled line shows the co-culture with 36104 DC. Results are representative for
3 indepentent experiments.
doi:10.1371/journal.pone.0010800.g001
Type II NKT Cells
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the absence of B7-H1 on TNF-DC. Simultaneously, IL-4 and IL-
13 concentrations were markedly increased in WT TNF-DC-
injected mice compared to control mice but significantly amplified
using B7-H1-deficient TNF-DC. These findings are in line with
the reduced disease course and support the notion of an increased
induction of IL-4 and IL-13 producing cells in the absence of
inhibitory B7-H1 on DC.
To identify the cell type responsible for increased IL-4 and
IL-13 production upon transfer of TNF-DC, CD1d2/2 mice as
well as Ja2812/2 were used as recipients of TNF-DC injections.
CD1d2/2 mice were described previously to lack type I and type
II NKT cells, whereas Ja2812/2 are deficient for the Vb14-Ja18
NKT (type I) cell population [28,29]. After three injections of WT
or B7-H12/2 TNF-DC in CD1d2/2 mice serum samples were
taken and subjected to cytokine quantification by ELISA.
Although Ja2812/2 mice have a bias towards high IFN-c and
lower IL-4 and IL-13 secretion as compared to the other mouse
strains, we observed comparable relative shifts for the production
of the cytokines IFN-c, IL-4 and IL-13 in both TNF-DC-treated
groups (Figure 5B). The absence of B7-H1 on TNF-DC did not
lead to an augmented protective cytokine production in CD1d2/2
mice. These data suggest an involvement of type I or II NKT cells
in cytokine release. To further dissect the implication of these two
cell subsets, we addressed selectively the role of type I NKT cells
by using Ja2812/2 mice. Serum ELISA revealed significantly
increased IFN-c, IL-4 and IL-13 concentrations in the B7-H12/2
TNF-DC injected mice compared to WT TNF-DC-injected
animals (Figure 5B). This indicates that type II NKT cells, but
not type I NKT cells were the main producers of type 2 cytokines
mediating protection from EAE.
Together, these data provide the first evidence of a direct
inhibitory function of B7-H1 on TNF-DC for the induction of type
Figure 2. B7-H12/2 DC have a higher tolerogenic potential than WT DC. A) 26106 or 36106 MOG35–55 loaded and TNF-matured WT or
B7-H12/2 DC were injected i.v. into WT mice 7, 5 and 3 days before EAE induction. Control mice were injected with PBS. On day 0, EAE was induced
and disease course was monitored daily. Results represent the average disease score of 4 mice per group and are representative for 4 independent
experiments. B) 2,56106 TNF-matured, but not MOG35–55 loaded WT or B7-H1
2/2 DC were injected i.v. into WT mice 7, 5 and 3 days before EAE
induction. Results represent the average disease score of 4 mice per group and are representative for 2 independent experiments.
doi:10.1371/journal.pone.0010800.g002
Table 1. Statistics of EAE.
Treatment Incidence
Mean Day of
Onset
Mean Maximal
Score
PBS 16/16 13.9 (+/22.1) 3.2 (+/20.9)
WT DC 17/21 15.4 (+/24.7) 1.7 (+/21.1)a
B7-H12/2 DC 10/20 15.0 (+/23.7) 0.9 (+/21.2)a,b
Mice were injected i.v. (days 27, 25, 23) with PBS, WT DC or B7-H12/2 DC and
on day 0 EAE was induced. The incidence, mean maximal score and mean day
of onset is shown.
aStatistically significant when compared with PBS group: p,0.001 by Student’s
t-test.
bStatistically significant when compared with WT DC group: p,0.05 by
Student’s t-test.
doi:10.1371/journal.pone.0010800.t001
Type II NKT Cells
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II NKT cells and the loss of this negative signal is correlated with
an amplified protective immune response.
NKT cell lines express PD-1 but only type II NKT cells are
stimulated by DC and are negatively regulated by B7-H1
To further investigate if especially type II NKT cells were
regulated by B7-H1 on DC we used different NKT cell lines,
which were either related to type I (KT12 and BW58 r/m CD28)
or type II NKT cells (XV19 and VIII24). All cell lines expressed
PD-1, the ligand for B7-H1, at comparable levels (Figure 6A). We
co-cultured DC from WT or B7-H12/2 mice with the different
cell lines and found that only the type II NKT cells responded to
the DC, which was indicated by the production of IL-2. Type I-
related cell lines did only respond to DC in the presence of the
CD1d-ligand aGC. The IL-2 response of the type II-related cells
was even higher in the absence of B7-H1 on the DC showing that
B7-H1 negatively regulates these cell lines (Figure 6B). It is of note
that also the type I NKT cell lines showed an increased IL-2
production in the presence of aGC by using DC that were
generated from B7-H12/2 mice (Figure 6B).
Taken together we could show that DC only activated type II
NKT cells by their endogenously expressed CD1d-ligands. This
interaction was regulated by B7-H1 on the surface of the DC and
independent of the PD-1 expression by the NKT cell lines.
Discussion
In this study we showed that absence of B7-H1 expression on semi-
mature DC improves active tolerance induction upon DC injection
into mice, which leads to the priming of protective peptide-restricted
CD4+ T cells and CD1d-restricted type I and II NKT cells as well as
the release of IL-10, IL-4 and IL-13. Injections of B7-H12/2 DC
induced higher amounts of protective cytokines, specifically from type
II NKT cells as indicated by the results fromCD1d2/2 and Ja2812/2
mice. Thus, our data point to an inhibitory role of DC-expressed
B7-H1 for type II NKT cells andMHC II/peptide-restricted CD4+T
cells but not type I NKT cells. The NKT cell line experiments may
indicate a lack of endogenous CD1d-ligands on the DC for
presentation to type I NKT cells but not type II NKT cells.
Tolerance induction by TNF-DC is predominantly dependent
on the presence of the MOG-peptide loading and thereby on
Figure 3. Injection of B7-H12/2 DC results in reduced frequency of neurantigen-specific IFN-c and IL-17 secreting cells in the CNS.
MOG35–55 loaded and TNF-matured WT or B7-H1
2/2 DC (2,56106) were injected i.v. into WT mice 7, 5 and 3 days before EAE induction. Control mice
were injected with PBS. After 15 days CNS mononuclear cells were harvested and CNS T cell infitration and cytokine production were investigated
using flow cytometry and ELISPOT assay. A) Dot blots are gated for live lymphocytes and inserted numbers represent the percentage of CD4+ and
CD8+ CNS infiltrating T cells of 3–5 pooled mice per group of one experiment. Results are representative for 2 independent experiments. B) ELISPOT
analysis of IFN-c (left) or IL-17 (right) production by infiltrating CNS cells after MOG35–55 peptide restimulation. Results are representative for 2
independent experiments with 3–5 pooled mice per group. * p,0.05, ** p,0.01, n.s. not significant.
doi:10.1371/journal.pone.0010800.g003
Type II NKT Cells
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MHC II/peptide-restricted CD4+ T cells, while CD1d-restricted
NKT cells also contribute to the protection, however, by
recognizing an endogenous CD1d-ligand from the DC that is
irrelevant for the EAE [2]. Immediately after the third DC
injection, CD4+ T cells and NKT cells released IL-4 and IL-13 to
create an immune-deviatory environment that counteracts the
Th1 and Th17 effector cells which mediate EAE. However, the
use of CD1d-deficient DC did not allow a distinction between
responses of type I or II NKT cells. Subsequently during the
response, IL-10-producing CD4+ T cells dominate among the
MOG-peptide specific populations in the spleens of mice that were
completely protected from EAE [3]. Intracerebral injections of
semi-mature DC were also able to delay or prevent EAE, as higher
numbers of IL-10-producing neuroantigen-specific lymphocytes
were generated in the periphery, thereby restricting IL-17
production in the CNS [30]. The surprising finding was that
obviously ‘‘matured’’ DC could still act tolerogenic, which did not
fit into the paradigm of DC maturation where immature DC were
postulated to be tolerogenic and mature DC to be immunogenic
[31]. This dilemma could be best circumvented by the proposal of
a third maturation stage that was termed semi-mature [1]. These
semi-mature DC expressed high levels of costimulatory molecules
such as CD80, CD86 and CD40, which were required for the
EAE-protection since immature DC were unable to protect. In
contrast to LPS-treated and thereby fully mature DC, semi-mature
DC did not release proinflammatory cytokines and were generally
described as low cytokine producers [3]. The question remained
whether the additional expression of coinhibitory molecules on
semi-mature DC could contribute to the tolerogenic functions.
We and others previously demonstrated that APC-derived B7-
H1 plays a critical negative regulatory role to T cell stimulation in
the context of autoimmune CNS inflammation [6,15,20,21,30].
Using B7-H12/2 mice in the MOG35–55 EAE model, earlier and
exacerbated primary neuroantigen-specific immune responses
were described ultimately leading to an aggravated disease course
accompanied by higher immune cell infiltration in the CNS of
Figure 4. B7-H12/2 DC induce more protective cytokines than WT DC. MOG35–55 loaded and TNF-matured WT or B7-H1
2/2 DC (2,56106)
were injected i.v. into WT mice 7, 5 and 3 days before EAE induction. Control mice were injected with PBS. 10 days after EAE induction spleen cells
were isolated and restimulated with different concentrations of MOG35–55. After 4 days of culture supernatants were tested by ELISA for IL-10, IL-13,
IL-17 and IFN-c. Results show the mean of 4 mice per group and are representative for 2 independent experiments with 4 mice per group.
doi:10.1371/journal.pone.0010800.g004
Type II NKT Cells
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B7-H1 deficient animals [21]. Thus, B7-H1 evolved as a crucial
immune-inhibitory molecule capable of downregulating neuroan-
tigen-specific T cell responses both in the periphery and the target
organ of autoimmune inflammation. Recently, this concept was
further corroborated by studies investigating the role of PD-1
ligands on different CNS APC applying a relapsing EAE model
[22]. Therefore, we speculated that mediation of T cell tolerance
induction might be altered in the absence of B7-H1 on APC
[4,11].
Surprisingly, we found here that in the absence of B7-H1 on the
semi-mature DC their tolerogenicity was further enhanced. The
enhanced release of protective cytokines could be attributed to
the rare population of CD1d-restricted CD4+ T cells, so-called
type II NKT cells. This is indicated by the use of specific type I
and II NKT cell lines and the fact that the increased serum
cytokine release of IL-4 and IL-13 after injection of B7-H1-
deficient DC returned to the levels of mice injected with WT-DC
when B7-H1-deficient DC were applied to CD1d2/2 mice which
lack both type I and II NKT cells. In contrast, Ja2812/2 mice
which lack only the Va14-Ja18+ type I NKT cells but not the type
II NKT cells [29], did show the serum cytokine increase. This is a
strong indication that type II NKT cells are the predominant cell
population that was affected by B7-H1 molecules on the DC. Type
II NKT cells are selected in the thymus but on CD1d molecules
instead of MHC II/peptide complexes. However, some authors
found that they may not express markers typical for type I NKT
cells such as NK1.1 [26,27,29] although this could not be
confirmed in a type II NKT cell TCR transgenic mouse [32]. This
may indicate the existence of NK1.1 negative and positive
subtypes of type II NKT cells. A role for B7-H1 (PD-L1)
interaction with PD-1 on type I NKT cells has recently been
indicated to be responsible for the induction of an anergic state of
type I NKT cells. This type I NKT cell anergy was defined as the
fact that type I NKT cells become refractory for further
stimulations by the ligand aGC after primary activation in vitro
[24,25]. The same anergic state is achieved after aGC injection in
vivo [33]. However, we could not observe this when using CD1d-
expressing DC for the type I and II NKT cell activation in vivo [2].
The discovery of sulfatide as an endogenous ligand for type II
NKT cells that has been shown to influence EAE [34] and this
may lead to anergy of type I NKT cells as shown in tumor and
liver disease models [35,36]. This opens the possibility that our
DC may present sulfatide or a similar endogenous ligand to
activate type II NKT cells leading to anergy or regulatory activity
of type I NKT cells as discussed elsewhere [37].
Additionally, the fact that aGC primed NKT cells also do not
polarize selectively into IL-4 or IFN-c releasing cytokines in vivo but
NKT cells do so when primed by differentially matured DC [2,38],
Figure 5. Strong increase of protective serum cytokines after injection of B7-H12/2 DC injection is mainly produced by type II NKT
cells. A) Splenocytes from WT and Ja2812/2 mice were stained for CD3 and NK1.1 and investigated by flow cytometry. Double positive cells (NKT
cells) were analyzed for PD-1 expression. B) MOG35–55 loaded and TNF-matured WT or B7-H1
2/2 DC (2,56106) were injected i.v. into WT, CD1d2/2 or
Ja2812/2 mice three times (on day 24, 22 and 0). Similarly, control mice were injected with PBS. Blood was collected 2 hours after the last DC
injection and serum cytokines were measured by ELISA for IFN-c, IL-17, IL-4 and IL-13. The results represent the average of 3 mice per group and are
representative for 4 independent experiments for the WT mice and for 2 independent experiments for CD1d2/2 and Ja2812/2 mice. * p,0.05,
** p,0.01, *** p,0.001, n.s. not significant.
doi:10.1371/journal.pone.0010800.g005
Type II NKT Cells
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indicates that the priming conditions by aGC or DC may
differentially affect type I and II NKT cell responses. This may be
explained by the fact that that in our previous experimental settings
[2], we did not distinguish between type I and II NKT cells.
However here, by using the specific NKT cell lines it became clear
that our in vitro generated DC do not carry an endogenous CD1d-
ligand recognized type I NKT cell lines. In contrast, the same DC
were readily detected by the type II NKT cell lines. However, type I
NKT cells responded readily when pulsed with exogenous aGC.
The differential capacities of our DC to stimulate type II but not
NKT cells by an endogenous ligand raises the question, whether this
presentation is due to the specific semi-mature stage of the DC. In
our previous work we found already that BM-derived DC present
an endogenous ligand on CD1d molecules [2]. Although we did not
distinguish between type I and II NKT cells, these data clearly
indicated that also LPS-maturation leads to the presentation of an
unknown endogenous ligand. Therefore we speculate that a
surrogate ligand, specific for type II NKT cells, is presented by
DC to polarize these cells in a similar pattern as observed for Th1
and Th2 of MHC II restricted T cells.
Selective ligands for type I and II NKT cells may also point to
differential interactions of CD1d-expressing APC populations in
vivo. Especially CD1dhigh-expressing marginal zone B cells are also
likely candidates to capture aGC after i.v. injection and to interact
with type I NKT cells [39,40]. Here we found that the CD1d-
restricted CD4+ T cells are negatively regulated by B7-H1 when
expressed by DC presenting an endogenous ligand but did not
observe an effect on type I NKT cells in vivo or in vitro on the
different NKT cell lines. In mice aGC injection leads to type I
NKT cell-mediated DC maturation [41,42]. All together, this
indicates that the application of the surrogate antigen aGC has
different antigenic and immunogenic properties as compared to
physiological endogenous ligands by DC.
Together out data point to a novel role of B7-H1 molecules
expressed by tolerogenic DC. Unexpectedly, B7-H1 inhibits
selectively type II NKT cells but not type I NKT cells. In the
absence of this coinhibitory molecule on tolerogenic DC even
more protective cytokines are produced. Understanding the
mechanisms of differential DC function and the impact of central
coinhibitory molecules like B7-H1 in the context of CNS
Figure 6. NKT cell hybridoma cells express PD-1 but only the type II NKT cells are stimulated by DC and are negatively regulated by
B7-H1. A) NKT cell hybridoma cells s were stained for PD-1 and analyzed by FACS. The shaded histogram shows the isotype control staining and the
black line shows PD-1 staining. B) DC from WT and B7-H12/2 mice were co-cultured with the indicated NKT hybridoma cells in the presence or
absence of aGC (10 ng/ml). After 24 hours, the supernatants were tested for IL-2 content by ELISA. Results show 1 out of 4 representative and
independent experiments. ** p,0.01.
doi:10.1371/journal.pone.0010800.g006
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autoimmunity should help applying tolerogenic DC in targeted
therapies. Selective induction of boosted tolerogenic properties
of DC by modulating PD-1/B7-H1 interactions and thereby
constraining induction and development of potentially pathogenic
T cells might depict an attractive approach in cell-based therapy.
Materials and Methods
Ethics statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal work was approved by the
appropriate committee (Regierung von Unterfranken, approval
no. 55.2-2531.1-73/07).
Mice
Wild-type C57BL/6 mice were purchased from Harlan
Winkelmann (Borchen, Germany). B7-H12/2 mice were kindly
provided by L. Chen (Baltimore, USA), CD1d2/2 by L. van Kaer
(Vanderbilt University School of Medicine, Nashville, TN),
Ja2812/2 by M. Taniguchi (Institute of Physical and Chemical
Research, Kanagawa, Japan) and 2D2 Tg mice by V. K. Kuchroo
(Harvard Medical School, USA). Mice were bred and housed
under specific pathogen-free conditions in the animal facilities of
the Department of Neurology and the Department of Virology
and Immunobiology in Wu¨rzburg according to German guidelines
for animal care.
Generation and maturation BM-DC
DC were generated from BM cells derived from C57BL/6 or
B7-H12/2 mice as described [43]. Briefly, BM cell were flushed
from femur and tibia and cultured with 10% supernatant of a
GM-CSF producing cell line and used at day 6–10 of culture. For
DC maturation, cultures were pulsed for 4 h with TNF (500 U/ml;
PeproTech) together with MOG35–55 peptide before intravenous
injection into the tail vein of mice.
T-cell proliferation assay
BM-DC fromWTand B7-H12/2mice were stimulated with TNF
and loaded with MOG35–55 as described above. MOG35–55-specific
TCR transgenic CD4+ T-cells from 2D2 mice were enriched from
the spleen with Easy Step CD4+ T cell enrichment Kit (Stemcell) and
stained with CFSE (Invitrogen) according to the manufacturer’s
instructions. 46105 T cells were co-cultured with 36104, 16104 or
without DC in 96-well plates. After 4 days the cells were stained with
anti-CD4 and CFSE-dilution of the CD4+ cells was analysed by
FACS.
Induction of EAE and injections of DC
MOG35–55 peptide (EVGWYRSPFSRVVHLYRNGK; synthe-
sized and HPLC purified by R. Volkmer, Charite, Berlin,
Germany) was used for active induction of EAE. Age- and sex-
matched C57BL/6 or CD1d2/2 mice were immunized s.c. with
200 mg MOG35–55 emulsified in CFA (Sigma-Aldrich, Steinheim,
Germany) that was further enriched with Mycobacterium tuberculosis
H37RA (5 mg/mL) (Difco, Detroit, MI, USA). In addition, mice
were injected i.p. with 400 ng pertussis toxin (List Biological
Laboratories, Laboratories, Campbell, CA, USA) at the time of
immunization (day 0) and 48 h later. Using this standard
immunization protocol, we observed a typical chronic disease
course, for which clinical signs of disease were monitored daily and
scored based on the following scale (EAE score): 0, no disease; 1,
limp tail; 2, hind limp weakness; 3, hind limp paralysis; 4, hind and
fore limp paralysis; 5, moribund or death. 2–36106 stimulated and
MOG pulsed DC were injected intravenously repeatedly at days
27, 25 and 23 before EAE induction (day 0).
Isolation of spleen cells and preparation of CNS
mononuclear cells
For isolation of CNS mononuclear cells, mice were perfused
through the left cardiac ventricle with cold PBS, brains were
dissected and spinal cords were flushed out with cold PBS. CNS
material was cut into pieces and mononuclear cells were recovered
from the interface of a 30–50% percoll gradient centrifuged for
30 min at 5000 rpm. Cells were washed and resuspended in
culture medium for further analysis.
Single cell suspensions of splenocytes were obtained by mashing
the spleens of donor mice through a 70 mm strainer and
subsequent lysis of red blood cells with ACK buffer (150 mM
NH4Cl, 10 mM KHCO3, 0,1 mM EDTA). Splenocytes were
cultured in serum-free HL-1 medium (Lonza) supplemented with
Penicillin (100 U/ml, PAA), Streptomycin (100 mg/ml, PAA),
L-Glutamin (2 mM, PAA) and b-mercaptoethanol (50 mM,
Sigma).
Flow cytometry
BM-derived DC, NKT-cell cell lines, Splenocytes or CNS
derived cells were stained with surface antibodies (anti-B7-H1-PE,
anti-CD80-FITC, anti-CD86-FITC, anti-CD40-PE, anti-MHC
II-PE, anti-CD3-FITC, anti-NK1.1-PerCP-Cy5.5, purchased
from BD Pharmingen; anti-B7-DC-PE, anti-PD-1-PE, anti-CD4-
PerCp, anti-CD8-PE, purchased from eBioscience) in the presence
of FccRII/FccRIII-specific antibody (clone 2.4G2) to block
unspecific binding. FACS datawere collected on FACS Calibur
cytometer (BD Biosciences) and analyzed using FlowJo software
(TreeStar) version 7.2.1.
ELISA and ELISPOT
For the measurement of cytokine responses by ELISA, 46105
splenocytes depleted from erythrocytes were cultured in vitro in
the presence of different concentrations of MOG35–55 peptide
(0–20 mg/ml) and supernatants were collected after 3 days. Sera
were collected 2 h after the third immunization. Samples were
analyzed for cytokine content using ELISA kits for IL-4, IL-10,
IFN-c (BD Pharmingen), IL-13 and IL-17 (eBioscience).
For ELISPOT assays, 56104 CNS cells per well were
stimulated with 10 mg/mL MOG35–55 peptide and cultured for
24 h in 96-well-plates. ELISPOT assay was performed according
to the manufacturer’s instructions (for IFN-c: BD Pharmingen; for
IL-17: eBioscience). Spots were counted using a Wild Heerbrugg
M3Z dissecting microscope or evaluated by CTL Europe GmbH
(Aalen, Germany).
NKT cell line assay
The following NKT cell lines were used: KT12 [44], VIII24
and XV19 [26], BW58 r/m CD28 [45]. NKT cell lines were
cultured in RPMI with L-glutamin (GIBCO) containing 5% FCS,
100 U/ml Penicillin/Streptomycin, 0.1 mM non-essential ami-
noacids, 1 mM Na-pyruvate and 5 mM b-mercaptoethanol. For
the co-culture experiments the cell lines were cultured with TNF-
matured DC derived from WT or B7-H12/2 mice in medium
containing GM-CSF. 56104 cells from the cell lines KT12, BW58
r/m CD28 or VIII24 or 16104 cells from the XV19 cell line in an
96 well plate (round bottom) for 24 hours with the DC. As positive
control 10 ng/ml aGC (Alexis Biochemicals) was added to the
culture. The supernatant of this culture was testet by ELISA for
IL-2 production (BD Pharmingen).
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Statistical analysis
Two-tailed Student’s t-test was used to determine the statistical
significance of difference. A value of p,0.05 was considered
significant. Error bars in figures represent standard deviations.
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